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Abstract 
Introduction: Prosthetic infection is a devastating complication of arthroplasty and carries significant economic 
burden. The objective of this study was to analyze the economic impact of prosthetic hip and knee infection in 
Portuguese National Health System. 
Material and Methods: Case-control study carried out from January 2014 to December 2015. The mean 
costs of primary arthroplasties and prosthetic revision surgeries for non-infectious reasons were compared 
with the costs of prosthetic infections treated with debridement and preservation of the prosthesis or with 
two-stage exchange arthroplasty.The reimbursement for these cases was also evaluated and compared with its 
real costs. 
Results: A total of 715 primary arthroplasties, 35 aseptic revisions, 16 surgical debridements and 15 revisions 
for infectious reasons were evaluated. The cost of primary arthroplasties was 3,230€ in the hips and 3,618€ in 
the knees. The cost of aseptic revision was 6,089€ in the hips and 7,985€ in the knees. In the cases treated with 
debridement and implant retention the cost was 5,528€ in the hips and 4,009€ in the knees. In cases of 
infections treated with a two-stage revision the cost was 11,415€ and 13,793€ for hips and knees, respectively. 
Conclusion: As far as we know this is the first study that analyzes the economic impact of prosthetic infection 
in the Portuguese context. Although direct compensation for treating infected cases is much lower than 
calculated costs, infected cases push the overall hospital case-mix-index upwards thus increasing financial 
compensation for the entire cohort of treated patients. This knowledge will allow for more informed decisions 
about health policies in the future. 
Key words: prosthetic joint infection, Portugese National Health System 
Introduction 
Prosthetic join infection (PJI) is widely 
acknowledged as the most feared complication after 
total joint replacement. Despite modern preventive 
strategies, infection rates seem to be on the rise after 
total hip (THA) and knee (TKA) arthroplasty [1, 2]. 
Late infections occurring many years after index 
surgery are also becoming more common as the 
number of people living with some kind of total joint 
arthroplasty is increasing [3]. 
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PJI is consistently associated with significant 
medical implications for the patient thus becoming a 
source of substantial burden not only for patients but 
also for hospitals and healthcare systems. As the 
requirements for total joint arthroplasty have been 
and are expected to steadily increase, so will the 
economic burden of infection [4, 5]. 
The real cost of treating an infected joint is not 
easy to ascertain. Naturally, it depends on a lot of 
variables such as the specific type of treatment, 
patient co-morbidities and even bacteria related 
factors such as antibiotic susceptibility profile. The 
full spectrum of economic impact comprises the more 
commonly reported direct in-hospital costs, but also 
outpatient direct costs (follow-up visits, 
rehabilitation, pharmacy, etc.) and even indirect costs 
that are virtually impossible to accurately assess, such 
as productivity loss, work absenteeism of the patient 
or even his caregivers. 
Nevertheless, setting some kind of standard is 
critical to guide the rational use of existing economic 
resources and provide cost-effective care policies. Our 
primary goal is to provide baseline measurements of 
direct in-hospital costs of treating infection after total 
hip and knee arthroplasty in the Portuguese public 
health system and compare them with uneventful 
primary and aseptic revision arthroplasty. A 
secondary goal is to assess how these costs compare to 
current hospital reimbursement policy and its 
possible implications in the setting up of a reference 
center for the treatment of PJI. 
Material and Methods 
We conducted a retrospective case-control study 
at a single institution within the public Portuguese 
National Health System. We focused on a 2-year time 
period between January/2014 and December/2015. 
All hip or knee arthroplasty surgeries, either primary 
or revision, were identified on the institutional 
administrative electronic databases.  
Cases were then separated into four different 
groups: 1) Uneventful primary surgery; 2) Aseptic 
revision surgery; 3) PJI treated with debridement, 
antibiotics and implant retention (DAIR) and; 4) PJI 
treated with two-stage revision surgery. The first two 
groups, where there was no infection, served as 
controls. All groups were also further subdivided into 
hip or knee arthroplasty. 
Simple demographic and clinical data were 
obtained by reviewing electronic medical records. We 
also collected treatment related variables with impact 
to the final cost calculation such as the total length of 
stay and/or duration of stay in intensive care or 
orthopedic ward, as well as the duration of stay in the 
operating room. 
Administrative and economic data was derived 
from institutional databases and was obtained by two 
independent non-medical researchers (RF and SF), 
that were blinded to the patients’ diagnosis and 
outcome.  
For our primary goal, the calculation of the total 
cost per episode of care was allocated into two main 
parts: Hospital Stay including costs during the 
patient’s stay at the orthopedics department or 
intensive/intermediate care units, and Operating Room 
(OR) that includes all expenses made during surgery.  
Hospital Stay includes costs with: 1) Staff - costs 
based on the duration of hospital stay and labor cost 
for each health professional; 2) Ward costs - indirect 
costs with maintenance, meals and accommodation; 3) 
Materials - average costs with clinical consumables; 4) 
Diagnostic tests - costs stipulated for imaging, 
microbiology, blood tests, etc.; 5) Medication - 
pharmaceuticals dispatched separating Antibiotics. 
Operating Room costs includes: 1) Staff - costs 
based on the duration of surgery and labor cost for 
each health professional involved; 2) OR costs - costs 
of equipment, structure and general and clinical 
support specific for each surgery; 3) Clinical Materials - 
average costs with clinical consumables including the 
implants used. 
With all these variables in mind, final costs were 
calculated for each case and average price for each of 
the previously differentiated groups are reported in 
Euros (€). 
With respect to our secondary goal, we analyzed 
together with the Orthopedic Department 
management the existing reimbursement 
methodology and rules in effect during the study 
period. A fixed price is payed for each inpatient 
treated regardless the patient specific diagnosis. This 
price is defined according to the available national 
health budget, with adjustments for the two major 
types of admissions (elective and emergency) and 
hospital classification within the National Health 
System (hospitals are classified regarding the 
dimension, scale, specialization and education). This 
fixed price is further multiplied by a factor of the 
hospital case-mix index (CMI). Each treated patient is 
given a complexity score (relative value) according to 
diagnosis related group (DRG) classification (All 
Patient Refined DRG). The hospital CMI takes into 
consideration all inpatients episodes of a hospital 
reflecting their diversity and clinical complexity. It 
can be used as hospital output measure and also to 
adjust the average cost per patient. 
Results 
In the study time period, we identified a total of 
828 cases of hip or knee arthroplasty related surgeries. 
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Patients who underwent tumor arthroplasties (n=4), 
those whose main reason for hospital admission was 
not orthopedic (n=2), as well as patients who had 
unrelated procedures or complications during the 
same hospitalization (n=5) were excluded from the 
final analysis. We also excluded those in which we 
were not able to obtain the fundamental economic 
data (n=36).  
Ultimately, 781 patients were included in this 
study. In the first group of uneventful primary 
arthroplasties there were 715 patients (459 TKA, 256 
THA). In the second group of revision surgery due to 
aseptic failure, 35 patients were studied (13 TKA, 22 
THA). Every TKA revision surgery included in this 
study was complete, meaning both femoral and tibial 
parts were revised. However, regarding THA, only 
four cases had both femoral and acetabular 
components revised. For more accurate and fair 
comparison with infected cases, partial and complete 
revisions costs are discriminated.  
Among the 31 PJI cases included, 16 patients 
(eight TKA and eight THA), were treated with 
debridement and implant retention and 15 patients 
(eight TKA and seven THA) were treated with a 
two-stage exchange protocol.  
Basic demographic and clinical data of the cohort 
are detailed for TKA cases in table 1 and THA cases in 
table 2. There was no statistical difference between 
cases and controls with respect to age, gender 
proportion and ASA score. 
Economic calculations are expressed in table 3 
for knee cases and table 4 for hip cases. It is possible to 
observe that the average cost of uneventful primary 
arthroplasty was slightly higher for TKA (3,618€) 
compared to THA (3,230€).  
The cost of treating an acute infection with 
debridements, antibiotics and implant retention, 
was on average 4,009€ for TKA and 5,528€ for THA. If 
we consider these together with the costs of primary 
joint replacement, infection in the early postoperative 
period more than doubles the cost of an uneventful 
joint replacement. 
The average cost of revision knee surgery for 
aseptic reasons is 7,985€ which is around 2.2 times the 
cost of a primary TKA. On the other hand, the cost of 
aseptic revision hip surgery was 6,089€ considering 
all cases together and 7,840€ if we consider only the 
four cases where both components were revised. In 
summary, aseptic revision hip surgery costs around 
1.9 to 2.4 times the cost of primary THA. 
The total cost of two-stage exchange surgery for 
the treatment of PJI, considering both hospitali-
zations, is on average 13,793€ and 11,415€ for TKA 
and THA, respectively. This represents a cost of about 
3.5 times the cost of uncomplicated primary TKA and 
1.6 times the cost of revision TKA for aseptic reasons. 
Two-stage revision surgery in hips costs about 3.5 
times as much as primary uncomplicated THA and 
1.9 times as much as revision THA for aseptic reasons 
overall (roughly 1.5 times as much if we consider both 
components revisions only). 
 
Table 1. Basic demographic and clinical data for 488 TKA patients 
 Primary 
Arthroplasty 
Aseptic 
Revisions  
DAIR Two-stage 
Revision 
 n=459 n=13 n=8 n=8 
Age (years) 68 (47-88)  68 (58-80)  69 (62-76)  68 (39-77) 
Female Gender 372 (81%) 10 (77%) 5 (63%) 5 (63%) 
Length of Stay (days) 6  7  13 23 (14+9)  
 ICU stay (days) 0.03 0.5 0.1 1.2 
Time in the OR (hours) 2.24  2.6  4.29  7.9  
ASA score  2.3 2.5 2.5 2.7 
DAIR – Debridement, Antibiotics and Implant Retention;  
 
Table 2. Basic demographic and clinical data for 293 THA 
patients 
 Primary 
Arthroplasty 
Aseptic 
Revisions  
DAIR Two-stage 
Revision 
 n=256 n=22 (4+) n=8 n=7 
Age (years) 67(32-91)  66 (45-87)  73 (56-87) 62 (42-76)  
Female Gender 146 (57%) 10 (45%) 6 (75%) 3 (43%) 
Length of Stay (days) 7  21  9  22 (12+10) 
 ICU stay (days) 0.45 0.7 0.2 2.1 
Time in the OR (hours) 2.24  2.6  4.29  7.9  
ASA score 2.4 2.6 2.5 2.8 
DAIR – Debridement, Antibiotics and Implant Retention;  
+only 4 complete revisions 
 
Table 3. Economic Data on 488 TKA cases (average cost per 
patient in euros) 
 Primary 
Arthroplasty 
(n = 459) 
Aseptic 
Revisions 
(n = 13) 
DAIR 
(n = 
8) 
Two-stage 
Revision 
(n = 8) 
Total Costs 3,618 7,985 4,009 13,793 
Total Hospital Stay 1,024 1,289 2,677 4,388 
Staff  521 405 1,120 1,944 
Ward costs  262 151 135 1,141 
Materials  78 409 661 252 
Diagnostic Tests 62 126 78 433 
Medication  
(excluding antibiotics) 
83 94 78 108 
Antibiotics 4 19 553 239 
ICU stay  14 85 52 271 
Total Operating Room 2,594 6,696 1,332 9,405 
Staff 277 306 204 621 
OR costs 237 413 334 451 
Clinical Materials 
(including prosthesis)  
2,080 5,977 794 8,333 
DAIR – Debridement, Antibiotics and Implant Retention 
 
Table 5 presents the actual reimbursement for 
each of the four study groups. It is obvious that 
reimbursement is significantly lower than calculated 
costs for all groups. It covers 75%, 38%, 57% and 69% 
of the calculated costs for primary total joint 
arthroplasty, aseptic revision surgery, DAIR 
procedures and two-stage revision for infected cases 
respectively. The average loss per infected case varies 
between 2,068€ on average for DAIR cases and 7,515 € 
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on average for two stage revision surgery. During the 
study’s two-year period, total losses summed up 
33,088 € for 16 DAIR cases and 112,575 € for 15 
two-stage revision cases (145,663 € for infected cases 
together). 
 
Table 4. Economic Data on 293 THA cases (average cost per 
patient in euros) 
 Primary 
Arthroplasty 
(n = 256) 
Aseptic 
Revisions 
(n = 22 [4*]) 
DAIR 
(n = 
8) 
Two-stage 
Revision 
(n = 7) 
Total Costs 3,230 6,089 [7,840*] 5,528 11,415 
Total Hospital Stay 1,307 1,728 [1,739*] 3,923 4,584 
Staff  624 773 1,802 1,772 
Ward costs  407 151 [162*] 291 1,026 
Materials  94 404 1,028 274 
Diagnostic Tests  95 248 317 703 
Medication  
(excluding antibiotics)  
36 48 99 293 
Antibiotics  6 10 287 243 
ICU stay  45 94 87 273 
Total Operating Room 1,923 4,361 [6,101*] 1,605 6,831 
Staff  238 305 [351*] 304 464 
OR costs  292 392 208 719 
Clinical Materials 
(including the prostesis)  
1393 3,664 [5,358*] 1,093 5,648 
DAIR – Debridement, Antibiotics and Implant Retention;  
*-4 cases of total revision of acetabulum and femoral parts 
 
 
Table 5. Comparison between calculated costs and actual 
reimbursement for each group (TKA and THA considered 
together) 
 Mean Actual 
Reimbursement 
Reimbursement 
vs Costs 
proportion (%) 
Mean 
complexity 
score 
Complexity Score 
vs. Overall hospital 
CMI (%) 
Primary 
Joint 
Replacement 
2,623€ 75% 1.48 125% 
Aseptic 
Revisions 
2,564€ 38% 2.09 177% 
DAIR 
procedures 
2,700€ 57% 2.29 194% 
Two-Stage 
Exchanges 
5,168€ 69% 2.37 201% 
DAIR – Debridement, Antibiotics and Implant Retention 
CMI - case-mix index 
 
During the study time period, the overall 
hospital CMI was 1,2884 in 2014 and 1,0686 in 2015. 
Within this time period, there were 8,556 patients 
operated within the Orthopedic Department and 
overall department CMI was 1.25. We calculated the 
mean complexity score of the 16 DAIR cases 
contributed to a slight increase on the overall hospital 
CMI by 0.00033 in 2014 and 0.00012 in 2015, which 
lead to an increase in overall reimbursement for the 
hospital of 72,961€ during the study period. 
Considering the 15 two-stage revision cases, they also 
contributed to a slight increase on the overall hospital 
CMI by 0.00014 in 2014 and 0.00013 in 2015, which 
lead to an increase in overall hospital reimbursement 
of 100,173€ during the study period (173,134€ for 
infected cases together). 
Discussion 
It is no surprise that PJI management represents 
a substantial clinical and economic burden for 
hospitals, health-care systems and, most importantly, 
patients. Notwithstanding, despite its increasing 
relevance, there are but a few papers that debate this 
issue. As far as we are aware this is the first study that 
analyzes the economic impact of prosthetic joint 
infection within the Portuguese public health system. 
The full economic impact of PJI is ultimately 
much greater than the sum of all available parcels that 
can be objectively ascertained. Together with the 
commonly reported direct in-hospital costs, there are 
also less commonly reported outpatient costs and 
even indirect costs that are virtually impossible to 
assess, such as productivity loss and absenteeism 
from work of the patient or even his caregivers. 
Comparison between different papers is also made 
extremely difficult because of dramatic differences 
from one setting to another depending on the type of 
healthcare system and corresponding nation-specific 
economic standards. 
In a paper by Kurtz et al [2] including over 
150,000 PJI cases, the authors found that the average 
total hospital costs for infected hip revision were 
$72,700 United States dollars (USD) in 2001 and 
$93,600 USD in 2009. The average charges for infected 
knee revision were $58,700 USD in 2001 and $74,900 
USD in 2009. Treatment costs for PJI knee patients 
were generally lower than in the hip with an average 
difference of $5,965 USD. More recent studies from 
the US include not only inpatient but also outpatient 
services costs. In 2014, Kapadia et al[6] identified 21 
infected TKA and matched them to 21 non-infected 
patients who underwent uncomplicated primary 
surgery. Naturally, patients with PJI had significantly 
longer hospitalizations, more readmissions and more 
clinic visits. The mean total episode cost (fixed- and 
variable-direct costs) for patients with a surgical site 
infection was $116,383 USD (range, $44,416 to 
$269,914) which was significantly higher than a mean 
$28,249 USD(range, $20,454 to $47,957) in the matched 
group. Just recently, the same authors studied 16 
consecutive infected THA and matched them to 32 
non-infected patients. Similarly, the mean episode 
cost, was significantly higher in the infected group, 
$88,623 USD (range, $44,043-$158,202) when 
compared to the matched cohort, $25,659 USD (range, 
$13,595-$48,631)[7].  
Fernandez-Fairen et al [8] performed a 
systematic review of the literature and naturally 
found huge discrepancies in absolute values between 
publications according to its country of origin. 
Nonetheless, the cost for septic revision was 
consistently around 2-4 times more expensive than 
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primary surgery. It was also 1.5-3 times more 
expensive than aseptic revision surgery. 
Still, some PJI cases can be treated effectively 
without revision surgery. An Australian study by Peel 
et al[9], aimed specifically to calculate the cost 
associated with debridement and implant retention. 
For that, they focused on 21 prosthetic joint infections 
(12 THA and 9 TKA) and matched them to 42 control 
patients with uneventful primary joint replacements. 
They included inpatient expenses (human resources, 
operating theater, prosthesis, medical imaging, 
pathology, pharmacy, etc.) but also outpatient 
expenses including readmissions but also follow-up 
medical and nursing visits, medical imaging, 
pathology and pharmacy (including dispensed 
antibiotics). For patients with infection the total cost 
was $69,414 Australian dollars (AUD) compared with 
$22,085 AUD in controls, with significant differences 
across almost all areas of patient care. The cost of 
infection including index operation and costs of PJI 
management was 3.1 times the cost of uneventful 
primary arthroplasty in this study. 
Our study is unique since it examines the costs of 
different treatment options (DAIR or revision 
surgery), plus it compares them with a group of 
uncomplicated primary arthroplasties and aseptic 
revision surgery that serve as reference for costs 
comparison. Directly comparing absolute values 
between countries is unfair as economic environment 
are extremely different. Although Portugal spends 
8.9% of its gross domestic product (GDP) on health 
systems, which is only 0.1% less than average across 
Organization for Economic Co-operation and Development 
(OECD) countries, it has one of the lowest GDP and 
mean salaries in Europe[10]. As such, the authors 
believe that a fairer comparison of the cost of PJI and 
its treatment alternatives is to use the cost of 
uneventful primary arthroplasty as a reference 
measure.  
There are of course limitations to our study. Our 
analysis focuses exclusively on direct in-hospital costs 
and does not consider outpatient direct costs like the 
money spent on antibiotics, consultations and returns 
to the emergency room or indirect costs. Also, ours is 
a single center study. While this design is 
advantageous to ensure complete economic data for 
all patients included, it does not take into 
consideration heterogeneity in costs or even treatment 
approaches between institutions. 
Nevertheless, results of the current study 
highlight the substantial direct costs of prosthetic joint 
infection. It is clear that, even when infection is timely 
diagnosed and treated with debridement, appropriate 
antibiotics and implant retention, it is an expensive 
complication, more than doubling the costs of 
uncomplicated arthroplasty. In chronic infections 
requiring a two-stage exchange revision, costs rise to 
about 3.5 times that of a primary arthroplasty and 1.5 
times that of an aseptic revision. 
Knowledge of the costs associated with 
treatment of PJI is a critical part of optimizing existing 
resources in this era of worldwide financial concerns. 
The cost effectiveness of newer prophylactic measures 
can only be appreciated by knowing the real cost of 
infection. A major future challenge will be to define 
the role of different treatment strategies (DAIR, 
one-stage or two-stage revision surgery) taking in 
consideration the cost-effective perspective. 
Another major economic implication of PJI 
associated costs is how to organize infection care. It is 
widely recognized that dedicated specialized centers 
are able to obtain better results, probably in a more 
cost-effective way. In many health systems such as the 
Portuguese public health system, a major obstacle to 
the creation of such reference centers is the belief that 
there is a lack of adequate compensation for the 
treatment of infected cases thereby limiting 
management willingness to treat external cases. 
Findings of other European healthcare systems with a 
reimbursement methodology based on the DRG 
system such as Germany suggests this belief to be true 
as costs exceed financial receipts in infected cases [11].  
Our specific reimbursement methodology, as 
described previously in the methods section, adds 
another major variable. Although direct 
compensation for treating infected cases is much 
lower than calculated costs, infected cases do push the 
overall Hospital CMI slightly upwards thus 
increasing financial compensation for the entire 
cohort of treated patients.  
This small but tangible effect, seems to mitigate 
the apparent negative financial impact on the 
Orthopedic Department by increasing compensation 
for the entire cohort of patients treated within the 
entire hospital.  
In brief, the findings of this study may serve as a 
useful tool to more accurate resource allocation in PJI 
prophylaxis and management. Also, while they lack 
confirmation in larger cohorts as well as different 
treatment modalities such as one-stage revision 
surgery, our results seem to suggest the creation of a 
specialized center willing to receive external referred 
patients may not be as economically detrimental to 
the institution as previously thought.  
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